抗體藥物治療復(fù)發(fā)/難治性彌漫性大B細(xì)胞淋巴瘤的研究進(jìn)展

打開文本圖片集

中圖分類號R979.5 文獻(xiàn)標(biāo)志碼A 文章編號 1001-0408（2025）13-1677-06

DOI 10.6039/j.issn.1001-0408.2025.13.21

Research progress in antibody drug therapy for relapsed/refractory diffse large B-cellymphoma

SUN Yanyan，ZHAO Weichen，HE Chunyuan，XIA Yimiao，ZHOU Wei，ZHEN Yuanyuan，JIANG Junjie，WANG Facai[Dept.of Pharmacy，Lu'an Hospital of Anhui Medical University（Lu'an People’s Hospital），Anhui Lu'an 237005，China]

ABSTRACTDiffselargeB-celymphoma（DLBCL）isahighlyheterogeneousdisease.Although standardfirstlineregimens can cure 550% ofpatients，approximately one-third of them develop relapsed/refractory DLBCL（ .r/r DLBCL）.Consequently， immunotherapy targeting molecular abnormalities has become pivotal for managing r/r DLBCL. The results of this review show that withadvances inunderstanding DLBCLpathogenesisandthetumor immunemicroenvironment，antibody-basedtherapies haveevolvedrapidly，progressing from monoclonalantibodies（e.g.，rituximab，tafasitamab）to bispecificantibodies（e.g.， odronextamab，gloftamab，epcoritamab）andantibody-drugconjugate（e.g.，polatuzumabvedotin，loncastuximabtesirine）.These engineered agents enhance immune cytotoxicity and tumor-specific targeting，providing novel therapeutic options for r/r DLBCL patients.

KEYWORDSrelapsed/refractorydifuselargeB-cellymphoma；monoclonalantibodies；bispecificantibodies；antibody-drug conjugate

彌漫性大B細(xì)胞淋巴瘤（diffuselargeB-celllym-phoma，DLBCL）是非霍奇金淋巴瘤（non-Hodgkin'slymphoma，NHL）的主要亞型，約占NHL的 25%[1] 。（剩余15835字）